TKNO Q4 2022 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$8M-21.9% YoY

Gross Profit

$2M26.7% margin

Operating Income

-$14M-180.4% margin

Net Income

-$13M-168.5% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

-26.2%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$152M

Total Liabilities

$52M

Stockholders' Equity

$100M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$10M	-21.9%
Gross Profit	$2M	$5M	-57.6%
Operating Income	-$14M	-$5M	-198.6%
Net Income	-$13M	-$4M	-264.5%

Revenue Segments

Lab Essentials

$7M88%

Clinical Solutions

$772,00010%

Other Product

$185,0002%

Geographic Segments

UNITED STATES

$8M96%

Non-US

$277,0004%